Evidence map›Paper›PMID 34475032›Full record

ArticleDiabetes care2021

Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women.

Yilin Yoshida, Zhipeng Chen, Robin L Baudier, Marie Krousel-Wood, Amanda H Anderson, Vivian A Fonseca, Franck Mauvais-Jarvis

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Impact of diabetes mellitus on the menopausal experience: A scoping review.Diabetic medicine : a journal of the British Diabetic Association · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yilin YoshidaSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA yyoshida1@tulane.edu.ORCID 0000-0003-0441-2697
Zhipeng ChenDepartment of Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Robin L BaudierDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Marie Krousel-WoodDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Amanda H AndersonDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA.
Vivian A FonsecaSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA.ORCID 0000-0002-3381-7151
Franck Mauvais-JarvisSection of Endocrinology and Metabolism, Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA.ORCID 0000-0002-0874-0754
Tulane University · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Katherine Teresa Mills · 2016 to 2026
$25.3M
Tulane Building Interdisciplinary Research Careers in Women's Health (BIRCWH)K12HD043451 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI KROUSEL-WOOD, MARIE · 2002 to 2023
$9.9M
Targeting the estrogen receptor-α to protect functional β-cell mass in womenR01DK074970 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI Franck Mauvais-Jarvis · 2007 to 2026
$6.0M
The Gut Microbiome and The Metabolome in Chronic Kidney DiseaseR01DK107566 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI ANDERSON, AMANDA HYRE, WU, GARY D. · 2016 to 2020
$2.8M
Measures of Fibrosis and Clinical Outcomes in Chronic Kidney DiseaseR01DK104730 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI ANDERSON, AMANDA HYRE · 2015 to 2019
$1.9M
Repurposing estrogens to improve pancreatic islet transplantationR01DK107444 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI MAUVAIS-JARVIS, FRANCK · 2016 to 2019
$1.5M
The role of the androgen receptor in insulin secretionI01BX003725 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI MAUVAIS-JARVIS, FRANCK · 2018 to 2022
–
BLRD VA I01 BX003725NICHD NIH HHS K12 HD043451NIDDK NIH HHS R01 DK074970NIDDK NIH HHS R01 DK104730NIDDK NIH HHS R01 DK107444NIDDK NIH HHS R01 DK107566NIGMS NIH HHS P20 GM109036NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveEarly menopause may be associated with higher cardiovascular disease (CVD) risk. Type 2 diabetes mellitus (T2DM), coupled with early menopause, may result in even greater CVD risk in women. We examined CVD risk in women with early compared with normal-age menopause, with and without T2DM overall, and by race/ethnicity. RESEARCH DESIGN AND

methodsWe pooled data from the Atherosclerosis Risk in Communities study, the Multi-Ethnic Study of Atherosclerosis, and the Jackson Heart Study. We included women with data on menopausal status, menopausal age, and T2DM, excluding pre- or perimenopausal women and those with prevalent CVD. Outcomes included incident coronary heart disease (CHD), stroke, heart failure (HF), and atherosclerotic cardiovascular disease (ASCVD) (CHD or stroke). We estimated the risk associated with early (<45 years) compared with normal-age menopause using Cox proportional hazards models. Covariates included age, race/ethnicity, education, BMI, blood pressure, cholesterol, smoking, alcohol consumption, antihypertensive medication, lipid-lowering medication, hormone therapy use, and pregnancy history.

resultsWe included 9,374 postmenopausal women for a median follow-up of 15 years. We observed 1,068 CHD, 659 stroke, 1,412 HF, and 1,567 ASCVD events. T2DM significantly modified the effect of early menopause on CVD risk. Adjusted hazard ratios for early menopause and the outcomes were greater in women with T2DM versus those without (CHD 1.15 [95% CI 1.00, 1.33] vs. 1.09 [1.03, 1.15]; stroke 1.21 [1.04, 1.40] vs. 1.10 [1.04, 1.16]; ASCVD 1.29 [1.09, 1.51] vs. 1.10 [1.04, 1.17]; HF 1.18 [1.00, 1.39] vs. 1.09 [1.03, 1.16]). The modifying effect of T2DM on the association between early menopause and ASCVD was only statistically significant in Black compared with White women.

conclusionsEarly menopause was associated with an increased risk for CVD in postmenopausal women. T2DM may further augment the risk, particularly in Black women.

Indexed as

AtherosclerosisCardiovascular DiseasesCoronary DiseaseDiabetes Mellitus, Type 2Child, PreschoolFemaleHumansMenopausePostmenopauseRisk Factors

Identifiers

PMID34475032
PMCPMC8546283
OpenAlexW3196703935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.